Sign in →

Test Code GBACC Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody, Cell-Binding Assay, Spinal Fluid


Specimen Required


Container/Tube: Sterile vial

Preferred: Collection vial number 1

Acceptable: Any collection vial

Specimen Volume: 1 mL


Useful For

Evaluating patients with suspected autoimmune encephalitis and autoimmune epilepsy using spinal fluid specimens

Method Name

Cell-Binding Assay (CBA)

Reporting Name

GABA-A-R Ab CBA, CSF

Specimen Type

CSF

Specimen Minimum Volume

0.4 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
CSF Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Clinical Information

Gamma-amino butyric acid type A (GABA-A) receptor autoantibodies are highly predictive of GABA-A receptor autoimmune encephalitis. Patients who are seropositive for GABA-A receptor encephalitis have characteristic clinical-radiologic presentations including frequent seizures and multifocal lesions in the white matter. The majority of patients are treatable with immunotherapy.

Reference Values

Negative

Interpretation

Seropositivity for gamma-amino butyric acid type A receptor autoantibodies supports the clinical diagnosis of autoimmune encephalitis with neurological presentations including seizures and multifocal lesions in the white matter. A search for thymoma cancer and a trial of immunotherapy should be considered.

Cautions

Negative results do not exclude the diagnosis of autoimmune encephalitis. Only 2% of autoimmune encephalitis cases are associated with autoantibodies against gamma-amino butyric acid type A receptor.

Clinical Reference

1. O'Connor K, Waters P, Komorowski L, et al. GABAA receptor autoimmunity A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019;6(3):e552. doi:10.1212/NXI.0000000000000552

2. Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017; 88(11):1012-1020. doi:10.1212/WNL.0000000000003713

3. Waters P, Irani S. GABA-A receptor antibodies and their clinical associations. Neurology. 2017;88:1010-1011

4. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276-286

Method Description

Patient specimen is applied to a composite slide containing transfected and nontransfected EU90 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN, FA_112d-1_A_UK_C13, 02/25/2019)

Day(s) Performed

Monday through Sunday

Report Available

5 to 10 days

Specimen Retention Time

28 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86255

LOINC Code Information

Test ID Test Order Name Order LOINC Value
GBACC GABA-A-R Ab CBA, CSF 103715-9

 

Result ID Test Result Name Result LOINC Value
620231 GABA-A-R Ab CBA, CSF 103715-9

NY State Approved

Yes